Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts

Intuitive Surgical (ISRG) recently posted a +1.82% gain, outperforming major indices, though its prior performance lagged. The company anticipates strong upcoming earnings, with Q4 EPS projected at $1.99 (+8.15% YoY) and revenue at $2.41 billion (+18.2% YoY), alongside robust full-year growth forecasts. Despite these growth prospects, recent downward revisions in analyst estimates have led to a Zacks Rank of #4 (Sell), and ISRG trades at a significant premium with a Forward P/E of 53.77 and a PEG ratio of 3.69, both considerably above industry averages.

Analysis

Intuitive Surgical, Inc. (ISRG) demonstrated short-term strength with a 1.82% gain, outperforming the S&P 500, Dow, and Nasdaq in the latest session. However, this follows a period of significant underperformance, with the stock having lost 7.2% over the prior month while the S&P 500 gained 3.15%. Looking ahead, consensus estimates project robust growth, with upcoming quarterly revenue expected to increase 18.2% year-over-year to $2.41 billion and EPS to grow 8.15% to $1.99. Full-year forecasts are similarly strong, anticipating revenue and earnings growth of 17.06% and 11.31%, respectively. Despite this positive growth outlook, there are significant counter-signals. Recent downward analyst estimate revisions, though minor at a 0.03% dip in the consensus EPS over the last month, have contributed to a bearish Zacks Rank of #4 (Sell). Furthermore, the company's valuation is exceptionally high, trading at a Forward P/E of 53.77, more than double its industry's average of 23.98. Its PEG ratio of 3.69 also indicates a substantial premium compared to the industry average of 2.48, suggesting the stock is priced richly even when accounting for expected growth.

Key Decisions for Investors

• Given the stock's premium valuation and a Zacks #4 (Sell) rating, investors should be cautious, as the high expectations for growth are already priced in, making the stock vulnerable to any earnings disappointment.
• Monitor the upcoming earnings disclosure closely; a failure to meet the consensus revenue growth of 18.2% and EPS growth of 8.15% could trigger a significant price correction due to the high valuation multiples.
• Despite strong daily performance, the recent monthly lag and negative shift in analyst estimates warrant a review of existing positions, as these factors may signal near-term headwinds that could outweigh the positive long-term growth story.